TY - JOUR
T1 - Hip flexion weakness is associated with impaired mobility in oculopharyngeal muscular dystrophy
T2 - A retrospective study with implications for trial design
AU - Youssof, Sarah
AU - Schrader, Ronald
AU - Bear, David
AU - Morrison, Leslie
N1 - Funding Information:
This work was partly supported by a Muscular Dystrophy Association Clinical Research Training Grant (S.Y., #260590 ) and the NIH/NCRR/NCATS ( University of New Mexico Clinical and Translational Science Center , 8UL1TR000041 ).
Publisher Copyright:
© 2014 Elsevier B.V.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Oculopharyngeal muscular dystrophy (OPMD) is a rare myopathy for which validated outcome measures are lacking, posing a barrier to clinical trials. Our goal was to identify factors associated with impaired mobility in OPMD in order to guide development of surrogate endpoints in future clinical trials. One hundred forty-four individuals with OPMD were included in this retrospective, single-center study. We made novel use of parametric time-to-event analysis to model age at initial use of assistive device for ambulation. We hypothesized that limb weakness and other markers of disease severity are associated with earlier use of assistive devices. 23.6% of individuals (34/144) progressed to use of assistive devices (mean age 66.0 ± 9.6 y). Earlier age at assistive device was associated with hip flexion Medical Research Council grade ≤3 (. p <. 0.0001), earlier disease onset (. p <. 0.0001), and lack of blepharoptosis surgery (. p = 0.011). Markers of dysphagia severity were not associated with earlier progression to assistive devices. Our study is the first to show a statistical association between hip flexion weakness and impaired mobility in OPMD, indicating that hip flexion strength could be explored as a surrogate endpoint for use in clinical trials. Since severity of disease features may be discordant within individuals, composite outcome measures are warranted.
AB - Oculopharyngeal muscular dystrophy (OPMD) is a rare myopathy for which validated outcome measures are lacking, posing a barrier to clinical trials. Our goal was to identify factors associated with impaired mobility in OPMD in order to guide development of surrogate endpoints in future clinical trials. One hundred forty-four individuals with OPMD were included in this retrospective, single-center study. We made novel use of parametric time-to-event analysis to model age at initial use of assistive device for ambulation. We hypothesized that limb weakness and other markers of disease severity are associated with earlier use of assistive devices. 23.6% of individuals (34/144) progressed to use of assistive devices (mean age 66.0 ± 9.6 y). Earlier age at assistive device was associated with hip flexion Medical Research Council grade ≤3 (. p <. 0.0001), earlier disease onset (. p <. 0.0001), and lack of blepharoptosis surgery (. p = 0.011). Markers of dysphagia severity were not associated with earlier progression to assistive devices. Our study is the first to show a statistical association between hip flexion weakness and impaired mobility in OPMD, indicating that hip flexion strength could be explored as a surrogate endpoint for use in clinical trials. Since severity of disease features may be discordant within individuals, composite outcome measures are warranted.
KW - Mobility impairment
KW - Natural history
KW - Oculopharyngeal muscular dystrophy
KW - Outcome measures
KW - Time-to-event analysis
UR - http://www.scopus.com/inward/record.url?scp=84924288881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924288881&partnerID=8YFLogxK
U2 - 10.1016/j.nmd.2014.11.010
DO - 10.1016/j.nmd.2014.11.010
M3 - Article
C2 - 25500011
AN - SCOPUS:84924288881
SN - 0960-8966
VL - 25
SP - 238
EP - 246
JO - Neuromuscular Disorders
JF - Neuromuscular Disorders
IS - 3
ER -